Phathom Pharmaceuticals Seeks Correction for VOQUEZNA Listings
Phathom Pharmaceuticals, Inc. has made a significant move by submitting a Citizen Petition (CP) to the U.S. Food and Drug Administration (FDA). The petition aims to request a correction regarding the listings of VOQUEZNA (vonoprazan) 10 mg and 20 mg tablets in the Orange Book. The primary purpose of this petition is to ensure that the listings reflect a full 10-year exclusivity period for New Chemical Entity (NCE) status, which is set to last until May 3, 2032.
Understanding the NCE Exclusivity for VOQUEZNA
Phathom holds a strong belief that applicable laws dictate a 10-year exclusivity period for NCEs from the date the FDA first approves a drug with vonoprazan. Consequently, this exclusivity period should extend to all products containing vonoprazan, including VOQUEZNA tablets. Correcting the listings in the Orange Book is essential to align them with the same NCE exclusivity period previously awarded to VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which were approved in May 2022.
Details of the Citizen Petition
The Citizen Petition emphasizes several key points. Firstly, the approval of VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK triggered the 10-year NCE exclusivity period by virtue of the GAIN Act, due to the fact that vonoprazan was never approved before that time. Therefore, products containing this active ingredient, such as VOQUEZNA tablets, should also qualify for the same exclusivity status. The exclusivity period extends until May 2032, preventing any Abbreviated New Drug Application (ANDA) or 505(b)(2) New Drug Application (NDA) referencing vonoprazan during this time frame.
Impact of the GAIN Act
The Citizen Petition further elaborates on the implications of the GAIN Act, which has played a pivotal role in extending the NCE exclusivity period for vonoprazan. This piece of legislation not only extends the exclusivity period but also reinforces the position that VOQUEZNA tablets deserve the same protections as their counterparts approved earlier. The specifics of the GAIN Act indicate that while there are certain limitations, they do not apply to the established 10-year exclusivity period already acknowledged by the FDA.
Public Policy Expectations
Phathom Pharmaceuticals is advocating for a correction that aligns with public policy mandates as explicitly outlined in the existing regulations. The company has requested that the FDA updates the Orange Book listings to correctly establish the exclusivity deadline as May 3, 2032. Through this step, Phathom hopes to ensure that the regulatory framework adequately recognizes the protections afforded to the vonoprazan-based products.
Statements from Phathom's Leadership
Terrie Curran, President and CEO of Phathom Pharmaceuticals, expressed confidence in the company's position. “We are committed to ensuring VOQUEZNA tablets receive the full exclusivity protections in accordance with the FDA's longstanding policies,” said Curran. She highlighted the critical importance of this correction, noting that it would enhance their existing patent term exclusivity, which is anticipated to stretch into 2030.
Next Steps for the Citizen Petition
Phathom anticipates that the Citizen Petition and the related information will appear on the regulations.gov website shortly. The FDA is obligated to respond to the petition within 180 days of its submission. Their response could take various forms: an approval of the petition, rejection, or a tentative reply detailing the reasons for any delays in making a decision. This structured process allows the FDA to comprehensively analyze the Citizen Petition under established protocols.
About VOQUEZNA and Its Applications
VOQUEZNA tablets utilize vonoprazan, representing a novel class of oral potassium-competitive acid blockers (PCABs). These medications serve an essential role in managing acid secretion within the gastrointestinal tract. The FDA has approved VOQUEZNA for various indications, including treating Erosive Esophagitis—commonly referred to as Erosive GERD—and alleviating heartburn associated with both Erosive GERD and Non-Erosive GERD. Additionally, VOQUEZNA is used in combination therapies for H. pylori infection alongside antibiotics like amoxicillin.
Phathom Pharmaceuticals Overview
Phathom Pharmaceuticals is dedicated to advancing therapeutics for gastrointestinal disorders. By securing exclusive rights to vonoprazan, Phathom is positioned as a leader in providing innovative solutions for patients experiencing heartburn and related conditions. The company’s commitment to research and development is evident in its ongoing efforts to enhance access to effective treatments for GI diseases.
Frequently Asked Questions
What is the purpose of Phathom's Citizen Petition?
The Citizen Petition aims to correct the Orange Book listings for VOQUEZNA tablets to reflect a full 10-year exclusivity period until May 3, 2032.
How does the GAIN Act influence VOQUEZNA's exclusivity?
The GAIN Act provides for a 10-year NCE exclusivity period, extending protections for vonoprazan and its associated products.
What are the expected next steps after the petition submission?
The FDA must respond within 180 days, potentially approving, denying, or providing a tentative response regarding the petition.
What indications is VOQUEZNA approved for?
VOQUEZNA is approved for treating Erosive Esophagitis, GERD-related heartburn, and it helps in the management of H. pylori infections.
How does Phathom Pharmaceuticals position itself in the market?
Phathom is dedicated to developing innovative treatments for gastrointestinal diseases, emphasizing effective solutions for patients dealing with related health challenges.
